Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Potential chemo-free therapy in triple-positive mBC with ribociclib

Wolfgang Janni • 14 Sep 2024
ESMO 2024
Breast Cancer Ribociclib
DETECT V

Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany, discusses the potential for chemo-free therapy in triple-positive metastatic breast cancer (mBC) by incorporating ribociclib. Ongoing results from the Phase III DETECT V trial (NCT02344472) and other randomized studies are eagerly awaited to determine the viability of this approach. If successful, ribociclib could become a standard first-line treatment for patients with triple-positive mBC, offering a less intensive alternative to traditional chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wolfgang Janni

Using ctDNA in breast cancer clinical trials
2:09
Using ctDNA in breast cancer clinical trials
Wolfgang Janni • 13 Mar 2025
SURVIVE: liquid biopsy-guided surveillance in early breast cancer
2:19
SURVIVE: liquid biopsy-guided surveillance in early breast cancer
Wolfgang Janni • 13 Mar 2025
The emerging role of ctDNA in screening & monitoring early breast cancer
0:41
The emerging role of ctDNA in screening & monitoring early breast cancer
Wolfgang Janni • 13 Mar 2025
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
1:44
Evaluating liquid biopsies in early breast cancer at St Gallen 2025
Wolfgang Janni • 13 Mar 2025

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals